Atherogenic lipoprotein particles can vary considerably in their cholesterol content, but each particle contains only one molecule of apoB-100 (or simply apoB). As a result, serum concentration of ...

LONDON, UK — Achieving LDL-cholesterol levels less than 50 mg/dL with drug therapy, compared with baseline levels, is associated with lowered rates of major adverse cardiovascular events (MACE), but ...

Japan: Researchers have found in a new study that higher levels of LDL-C oxidation are associated with increased plaque ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

Many randomized trials have established that the risk reduction for cardiovascular (CV) disease is proportional to the absolute reduction of low-density-lipoprotein cholesterol (LDL-C). Nevertheless, ...

A greater reduction LDL-C was seen for combo therapy; reductions also seen in all-cause mortality, major adverse CV events, stroke incidence. HealthDay News — Combination lipid-lowering therapy (LLT) ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

The best time to take psyllium husk for its benefits is typically before or during a meal, especially one containing fat.

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

Once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) therapy has moved into a new phase with Food and Drug ...